Following publication of the wet age-related macular degeneration (wAMD) pathway, NHS England has published new commissioning guidance regarding treatment pathways in macular oedema secondary to retinal vein occlusion (RVO). Members are encouraged to visit the NHS Futures Biosimilar Hub in order to view the guidance. If you are not already registered, you will need to join the workspace and view resources.
The treatment pathway aims to support NHS commissioners and their system partners in England with commissioning of best-value NICE approved treatments at the right point in the patient pathway.
These tools have been developed with input from an expert working group led by Louisa Wickham, National Clinical Director for Eye Care, and Luke Nicholson, Director of Medical Retinal Services at Moorfields NHS Trust. The group consisted of clinicians, commissioners, pharmacists, patients, and service managers across England.
As part of the implementation of medical retina pathways and ophthalmology biosimilars, you can also access a Q&A briefing document that includes questions about the pathways, patient consent, differences between the originator and biosimilars, frameworks, and more. This is available on the NHS Futures Biosimilar Hub.
We encourage members to use and share these resources to support the consistent implementation of the pathways and biosimilars in ophthalmology.